Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Lexeo Therapeutics (NASDAQ: LXEO) announced that CEO R. Nolan Townsend will present at the 44th Annual J.P.

Rhea-AI Summary

Lexeo Therapeutics (NASDAQ: LXEO) announced that CEO R. Nolan Townsend will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 7:30 AM PT in San Francisco.

The presentation will be webcast live on the company's investor website under the News & Events tab, and a replay will be posted on the website after the presentation.

Argus Dec 22 session

+2.71% close to close Open Argus

Details

News Market Reaction – LXEO

In the Dec 22 session, LXEO gained 2.71%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement centers on Lexeo’s planned presentation at the 44th J.P. Morgan Healthcare Confere...

Analysis

This announcement centers on Lexeo’s planned presentation at the 44th J.P. Morgan Healthcare Conference on January 14, 2026 at 7:30 AM PT. It extends a recent pattern of investor-facing events after significant financings, regulatory filings, and clinical updates. Investors may track how management frames its cardiovascular genetic medicine programs, balance sheet resources, and previously disclosed S-3 resale registration for 1,250,015 warrant shares when assessing longer-term implications.

Key Figures

Conference edition: 44th Presentation date: January 14, 2026 Presentation time: 7:30 AM PT

Conference edition

44th

Annual J.P. Morgan Healthcare Conference

Presentation date

January 14, 2026

Scheduled conference presentation

Presentation time

7:30 AM PT

J.P. Morgan conference session

Historical Context

5 past events · Latest: Dec 04

5 events

1. Dec 04

   KOL event announcement

   24h Move

   +4.6%

   Announcement of virtual KOL session at Global CVCT Forum focused on PKP2-ACM.

2. Nov 05

   Earnings and pipeline

   24h Move

   -1.8%

   Q3 2025 results with LX2006 FDA interactions, positive interim data, and financing.

3. Oct 20

   Offering closing

   24h Move

   -3.8%

   Closing of public offering and concurrent private placement totaling about $153.8M.

4. Oct 16

   Offering pricing

   24h Move

   -0.7%

   Pricing of public offering and pre-funded warrants to raise about $135M.

5. Oct 16

   Proposed offering

   24h Move

   -0.7%

   Announcement of proposed underwritten public offering and concurrent private placement.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

genetic medicine

1 terms

genetic medicine medical

"a clinical stage genetic medicine company dedicated to pioneering novel treatments"

Genetic medicine uses a patient’s DNA information or directly alters genes to prevent, treat, or cure diseases—think of it as fixing or reprogramming the biological “recipe” that makes cells behave. It matters to investors because these therapies can offer durable, sometimes one-time benefits that reshape markets and revenue models, but they also carry high research costs, regulatory hurdles, and uncertain commercial uptake that affect risk and valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics, will present at the 44^th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 7:30 AM PT in San Francisco, California.

The event will be webcast live under the News & Events tab in the Investors section of the Company’s website. A replay of the webcast will be available on the website following the presentation.

About Lexeo Therapeutics 
Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. The Company is advancing a portfolio of therapeutic candidates that take aim at the underlying genetic causes of conditions, including LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy, LX2020 for the treatment of plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need. 

Media Response: 
Media@lexeotx.com 

Investor Response:
Ashley Kaplowitz
akaplowitz@lexeotx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Lexeo Therapeutics (LXEO) present at the J.P. Morgan Healthcare Conference?

Lexeo will present on Wednesday, January 14, 2026 at 7:30 AM PT.

Who from Lexeo Therapeutics (LXEO) will present at the January 14, 2026 session?

Chief Executive Officer R. Nolan Townsend will present.

How can investors watch the Lexeo Therapeutics (LXEO) presentation on January 14, 2026?

The presentation will be webcast live under the News & Events tab in the Investors section of Lexeo's website.

Will a replay of the Lexeo Therapeutics (LXEO) J.P. Morgan presentation be available?

Yes. A replay will be available on the company's website following the presentation.

Where is the 44th Annual J.P. Morgan Healthcare Conference presentation taking place for Lexeo Therapeutics (LXEO)?

The presentation is scheduled in San Francisco, California during the conference.